Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone + sulbactam versus amoxicillin + clavulanic acid prophylaxis in caesarean section
PACTR202602520357441Recruiting
- Sponsor
- DANIEL OHU
- Start
- May 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ceftriaxone + sulbactam and amoxicillin + clavulanate in surgical site infection (SSI) (2 arms), sponsored by DANIEL OHU. Primary endpoint: surgical site infection. Started May 2025; status: recruiting.
02
Drugs
ceftriaxone + sulbactamamoxicillin + clavulanate
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on PACTR202602520357441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202602520357441.